Creative Biostructure can provide custom virus-like particles production services based on our advanced and leading Mempro™ Virus-like Particles (VLPs) platform. Creative Biostructure has an excellent research team with rich experience in VLPs production through these years, therefore, you can count on us for the high-quality VLPs and outstanding services.
One of the essential factors in VLPs production is the proper choice of VLPs expression systems. Creative Biostructure can deliver custom VLPs produced by various expression systems, and bacterial cells system is one of our most applied one.
Figure 1. TEM micrographs of the VLP sample generated by Escherichia coli (E. coli) system. (Journal of Biotechnology, 2016)
Our bacterial cells system has developed various commercial E.coli strains and expression vectors for high-quality non-enveloped VLPs production. VLPs with several kinds of structural proteins, including IBDV, VP2, VP3 and VP4-polyproteins can be generated by bacterial cells system as well. Mempro™ virus-like particles (VLPs) production in bacterial cells system not only conduct high-yield custom VLPs, but also provide reliable process control and scale-up services. In order to increase the VLPs expression levels and solubility, Creative Biostructure can use different fusion protein systems including GST fusion proteins. We also have investigated other efficient prokaryotic hosts such as Lactobacillus casei and Pseudomonas fluorescens. Compare to E.coli system, these two hosts are easily manipulated, produce high yield of active and soluble VLPs, and can perform large-scale cultivation. The major disadvantages of this expression system are its inability of post-translational modifications to recombinant proteins, inability of correct disulfide bonds formation, and low solubility. To overcome these problems, we also provide other expression systems for VLPs production including mammalian cells system, yeast cells system, insect cells system, and plant cells system.
Mempro™ virus-like particles (VLPs) platform provides comprehensive services including VLPs production, application, functionalization strategies and characterization. Please feel free to contact us for a detailed quote.
L. H. L. Lua, et al. (2016). High-throughput process development of an alternative platform for the production of virus-like particles in Escherichia coli. Journal of Biotechnology, 219: 7-19.
M. F. Bachmann and P. Whitehead. (2013). Active immunotherapy for chronic diseases. Vaccine, 31(14), 1777–1784.
A. Bouchie. (2013). . GSK plows ahead with EMA malaria vaccine submission. Nat. Biotechnol., 31: 1066.